Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 18, 2008

Thermo Fisher Scientific Teams Up with Toronto University for Cancer Proteomics Research

  • Thermo Fisher Scientific is collaborating with the University Health Network (UHN) related to cancer biomarker development. The UHN team will use the company’s LTQ Orbitrap™ and Quantum Ultra™ mass spectrometry systems.

    Thermo Fisher Scientific and the UHN will also maintain a cross-validation workflow to help legitimize new biomarkers. After the UHN team validates a cancer biomarker, they will send it to the Thermo Fisher Scientific Biomarker Research Initiatives in Mass Spectrometry Center for a second validation.

    The researchers will look for proteins in the secreted fluids of cancer cell lines. The partners believe that this approach will accelerate the validation of biomarkers, targeted assays, and ultimately the development of blood tests.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »